China has a remarkable new entry in the vaccine race

– There are about three dozen coronovirus vaccine candidates worldwide in human trials, all using the standard approach of a needle to deliver an injection. However, China has just approved the first nasal spray for human testing, Bloomberg reports. One expectation is that a spray may be more effective than a spray in preventing the spread of the virus through the respiratory tract, although scientists have a long way to go to find out what will happen. If nothing else, according to NASTV, nasal sprays will facilitate mass production and administration.

The spray, which uses a weak flu virus combined with coronovirus spike protein, is scheduled to begin Phase I trials in November with 100 human volunteers. It is China’s 10th vaccine candidate to reach the human-testing stage. Elsewhere, AstraZeneca states that it still plans to produce a vaccine by the end of the year, notwithstanding that it expects the test to be a temporary halt to the trial due to the participant’s illness, Wall Street Journal. The participant, a UK woman, has developed a neurological condition, and a review is underway to determine if it is related to the vaccine, per new York Times. (Economists think it makes sense to pay people $ 1,000 to get vaccinated.)